Medtronic Announces Plan to Spin Off Diabetes Business into Standalone Public Company

On May 21 local time, Medtronic announced,Plans to spin off its diabetes business into a brand-new independent company。Que Dallara, current Executive Vice President and President of Medtronic's Diabetes Business, will become the CEO of the new diabetes company.

Medtronic's diabetes business currently has more than8,000 employees, with a global commercial layout and dedicated innovation, manufacturing, clinical, and quality systems.For Medtronic and the new diabetes company, this strategic decision will enable Medtronic to focus more on high-profit growth markets.

Medtronic stated that the new diabetes company will be a leading, scaled, direct-to-consumer diabetes enterprise — as the only company capable of commercializing a complete intensive insulin management ecosystem, enabling people to break free from the constraints of diabetes and live their best lives.This spin-off is expected to enable the new diabetes company to focus more on investing in its product lines, as well as manufacturing scale and automation, positioning it for success in automated insulin delivery and smart multiple daily injection (MDI) systems., while expanding profit margins over time. The independent new diabetes company will have a shareholder base that matches its business and financial condition.

Medtronic stated that after this split, it willMore focused on innovation-driven growth, and is in a leading position in the medical system and among doctor customers.Medtronic is expected to benefit significantly from its scale and strategic commercial, manufacturing, and technological synergies. Collectively, these factors are anticipated to drive sustained organic revenue growth in the mid-single digits or higher, while accelerating profit leverage.

This spin-offIt is expected to 18 Completed within a month through a series of capital market transactions, giving priority to the adoption of an initial public offering(IPO)And the method of subsequent equity divestiture.

Medtronic is taking decisive and ongoing portfolio management and capital allocation actions, shifting more focus to the highest-profit growth drivers related to its core strengths. The company is building its growth momentum, advancing its innovation pipeline and "just-in-time" product launches, includingPulsed Field Ablation, Renal Denervation, Implantable Tibial Nerve Modulation, and Soft Tissue Robotics。

Medtronic Chairman and CEO Geoff Martha stated: "This marks an important step for Medtronic and our diabetes business in creating lasting value for Medtronic, our shareholders, customers, and patients."Active portfolio management is an important means to achieve our continuous growth and success. This decision allows Medtronic's portfolio to focus on our highest-margin, strongest-growth areas, which are also where our core competencies lie."I am also very optimistic about the future of the diabetes business. Que's outstanding performance in driving growth and innovation has laid a solid foundation for the success of the diabetes business, ensuring that the needs of diabetic patients worldwide are met."

Medtronic's latest financial report shows,In the fiscal year 2025, the company's revenue was $33.537 billion, a year-on-year increase of 4.9%.Among which, the diabetes business revenue was 2.755 billion US dollars, increasing by 11.5% year-on-year.The fastest-growing business in the niche sector。

In the fiscal year 2025,Diabetes business accounts for 8% of Medtronic's revenue，Accounting for 4% of Medtronic's departmental operating profitIt is expected that after the completion of the spin-off, Medtronic's adjusted gross margin will increase by approximately 50 basis points, and its adjusted operating profit margin will increase by approximately 100 basis points.